Laval, Québec, Canada, November 30, 2015 – Algorithme Pharma of the Altasciences Group, a full service provider focused on early stage clinical research, today announced the addition of Dr. Graham Wood, Executive Vice President, Phase I Clinical Development to the team.
Dr. Wood will be involved in all aspects of Phase I trials conducted at Algorithme Pharma. This key appointment reinforces Algorithme Pharma’s commitment to further expand its early stage clinical research offering. It also reflects the company’s goal to remain an industry leader in innovative solutions to meet the increasingly complex requirements of biopharmaceutical companies at this critical stage of drug development.
“We are very pleased that Dr. Wood has joined us; his exceptional track record and extensive experience in early phase clinical research will be key as we take our Phase I innovator business to the next level,” said Chris Perkin, CEO of the Altasciences Group.
Since finishing graduate school, Dr. Wood has focused on clinical pharmacology and has managed three new molecular entities from toxicology to Phase IIa, over twenty from first-in-human to Phase IIa and conducted over 200 clinical pharmacology studies. He has worked at a senior level for a number of leading CROs where he consulted with pharmaceutical and biotechnology companies on their drug development needs and accelerating the clinical development process, from first-in-man to proof of concept.
“For over 20 years, clients have been benefitting from Algorithme Pharma’s access to an extensive database of healthy, patient and special populations and comprehensive full service Phase I/IIa offering. Dr. Wood will focus on expanding and adapting our solutions to best meet client needs and further enhance our customers’ experience,” adds Mr. Perkin.
About Altasciences Clinical Research
Altasciences Clinical Research encompasses Algorithme Pharma in Montreal, QC, Vince & Associates Clinical Research in Overland Park, KS, as well as Algorithme Pharma USA in Fargo, ND, thereby making it one of the largest early phase clinical CROs in North America. With over 25 years of industry experience, Altasciences provides early phase clinical development services to an international customer base of biopharmaceutical and generic companies. Altasciences’ full service solutions offering in this critical stage of drug development includes medical writing, biostatistics, data management and bioanalysis.
For More Information
Director, Communications and Marketing